I feel like once we get a day where we go up 40+%, because were so close to news, that's when the excitement will spread through out the investor world and we'll start to see an actual run up.

Then .07 would be easy

Agreed!

Denial would have already happened!

Just waiting on the green light, then a week or two later we get news trials start and boom!

Than news of min IND filing! I'm so excited!!!

Expect the unexpected. Nobody else in the market expects news for BMSN except us.

Remember, all those stocks that went up 500+% this week, I bet only a handful of people saw it coming...which was why the price was sitting around .001ish and at .015 a day later.

Here’s a trend I noticed, check it out, maybe it will get your hopes up for any sort of news and stop you from pressing that sell button right before it pops!

1) News came out 2/5/13( Feburary)

21 days later….

2) News came out 2/26/13(Feburary)

21 days later….

3) News came out 3/18/13(March)

18 days later….

4) News came out 4/4/13(April)

32 days later…

5) News came out 5/6/13(May)

32 days later…

6) News came out 6/7/13(June)

It’s been 35 days since the last news…(july news next)

I think were due for some sort of news soon
Whether its news from the IND for HemaXellerate, the IND from the min technology, a progress update…I think koos has been pretty consistent with news and were overdue for some.

all support for the day gone....in 10 min

It is nice to keep seeing the bid grow even though there is no buying.

Nothing worse than small bids that get whacked early on

Go BMSN!
Lets keep this nice uptrend going with some green today! don't need much just a few ticks

Everything's looking great!

BMSN: A Diamond in the Rough

Bio-Matrix Scientific Group (BMSN) may very well be one of those life-changing stocks. This company catches the eyes of many investors who trade based on technical analysis as well as those who believe the fundamentals behind the stock. This opportunity presents itself once in a lifetime: that is, finding a stock with as little downside and as much upside as possible, and when looking at what BMSN has to offer, the upside is unlimited. This is a very exciting time and things will start to happen very fast.

First off lets meet your Advisory Board
Weiping Min, M.D.

Dr. Min is Associate Professor, Department of Surgery at the University of Western Ontario. His clinical research is focused on using siRNA to inhibit disease modalities, including cancer and organ rejection. He earned graduate and medical degrees from Nanchang University Medical School and the Ph.D. degree from Kyushu University.

Vladimir Bogin M.D.
Dr. Bogin is the President and CEO of Cromos Pharma, a contract research organization that specializes in biopharmaceutical clinical outsourcing. He was formerly the Director of Boehringer Ingelheim in charge of the phase IV program for Dabigatran Etexilate. He studied at the Yale University School of Medicine and the University of Rochester School of Medicine and Dentistry.

David James Graham White, M.D., Ph.D.
Dr. White is a member of the Surgery and Immunology faculty of The Schulic School of Medicine, University of Western Ontario. He is one of the leading experts on using regenerative medicine transplant procedures to treat pancreatic conditions, including diabetes. He is also the Chief Scientific Officer of Sernova Corp and was formerly a Therapeutic Area Head for Novartis. He received the B.Sc. degree from the University of Surrey and the M.D. and Ph.D. degrees from Cambridge University.

Fundamentals:

Bio-Matrix Scientific Group’s (BMSN) and their wholly owned subsidiary have taken major strides in the past seven months. The company has gone from initiating pre-clinical trials at the end of 2012 for HemaXellerate to potentially having two IND’s in progress. Here is a complete list of all that has been accomplished.

Milestones Achieved:

1) Regen Biopharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate™ Bone Marrow Failure Product
http://www.regenbiopharma.com/news/2013.01.24.html
2) Regen BioPharma Files Investigational New Drug (IND) Application with FDA on HemaXellerate™ Stem Cell Drug For Aplastic Anemia
http://www.regenbiopharma.com/news/2013.02.05.html
3) Bio-Matrix’ Regen Biopharma Executes LOI to Acquire Issued US Patent Covering Cancer Gene-Silencing Technology for its use in Treating Breast Cancer.
http://finance.yahoo.com/news/bio-matrix-regen-biopharma-executes-151230212.html
4) Regen BioPharma Recieves IND # From FDA for HemaXellerate
http://finance.yahoo.com/news/regen-biopharma-receives-ind-fda-135716810.html
5) Bio Matrix Scientific Group’s Regen Biopharma Acquires Cancer Vaccine Technology With Initial Focus on Breast Cancer
http://finance.yahoo.com/news/bio-matrix-scientific-groups-regen-123000619.html
6) Bio-Matrix Scientific Group’s Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program
http://finance.yahoo.com/news/bio-matrix-scientific-groups-regen-123000616.html

At times things may seem slow but in reality they are happening very fast!! Don’t miss this opportunity because you can’t wait a few months.

Upcoming Milestones:

All of these are happening within the next few months

1) Initiate HemaXellerate Trial: Q4 2013
2) File IND on Min technology: Q4 2013
3) Initiate Min technology Trail: Q4 2013



How Will BMSN Fund Clinical Trails?

***Remember that BMSN has $20,000,000 in funding just wairing for the trial of hemaXellerate from Southridge***

Bio-Matrix Scientific Group, Inc. Announces Newly Formed Stem Cell Subsidiary -- Regen BioPharma Inc., Secures $20,000,000 in Institutional Funding
Southridge Partners to Provide $20 Million in Funding for the Rapid Commercialization of Stem Cell Therapies
SAN DIEGO, CA--(Marketwire - Apr 30, 2012) - Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) announced today it has formed a new subsidiary, Regen BioPharma, Inc. Regen BioPharma has developed a vertically-integrated structure for acquiring patents, performing accelerating preclinical and clinical development, and licensing or selling technology developed to large pharma companies in the area of stem cells.
To date, Regen BioPharma has reviewed more than 20,000 US issued patents covering stem cell related subject matter, created a shortlist of 30 promising technologies for rapid commercialization, and currently is in negotiations to license several of these. Once the technology is secured, the Company anticipates partnering with industry leading scientists, physicians, and service providers to complete the Investigational New Drug (IND)-enabling work and begin clinical trials.
"In biotechnology in general, and specifically in the area of regenerative medicine, the biggest value creation occurs for shareholders when a company files an IND and obtains human data that provides proof of safety and efficacy," said David R. Koos, Chairman and Chief Executive Officer of Bio-Matrix. "We are assembling the team and capabilities to in-license and evaluate technologies rapidly, then to develop the regulatory package and initiate clinical trials. Our business model and partnerships will allow us to take cell therapy products from discovery to FDA Phase II clinical trials in as short a period as 18 - 24 months."
The Company also announced that it has secured $20,000,000 in financing from Southridge Partners II, LP of Ridgefield, Connecticut.
This agreement grants the Company the option to sell and obligates Southridge to purchase up to $20,000,000 of common stock over its term. The per share price will be determined based on market prices in accordance with an agreed upon formula and the Company is not obligated to draw on the facility.
The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission to register the resale by Southridge of any shares issued to it under the agreement. Subject to the effectiveness of the registration statement and the satisfaction of other customary conditions, the Company may draw on the facility from time to time, as and when it determines appropriate, in accordance with the timing and volume provisions set forth in the agreement.


Valuation once both Clinical Trials have been initiated:

These prices do not include hype for mergers, acquisitions, deals, etc…

Outstanding Shares= 2Billion
Drug in Phase 1= 40 million USD
$80,000,000 market cap / 2,000,000,000 shares =
.04 by the end of september

This is roughly a 1,500% increase from the current prices within the next few months. Anticipation alone should drive the price upward.

Bio-Matrix Scientific group has just entered quarter 4 of their fiscal year and thus far have achieved every aspect of their timeline on time if not earlier than expected.
Now lets be conservative, and say that only one drug made it to Phase II by the end of the year. This would put the BMSN market cap at about $140,000,000, yielding a share price of .07.

So if both drugs were to make it on to phase II by the end of the year you would be seeing a share price of a dime (.1) solely based on expected market cap of two Phase II drugs divided by the outstanding share number. That does not account for anticipation price of mergers, buyouts, and funding. The sky is the limit for this stock!

What is MinTechnology?

Take a look at his website! KNOW WHAT YOU OWN!!! He is the real deal!
http://publish.uwo.ca/~mweiping/

What is HemaXellreate?
http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf

Technicals:

Watch this quick video done by the brilliant guys at Bull Warrior Stocks and realize that the Stock is now in an uptrend. So for those of you looking for a firm investment with limited downside, BMSN is a great play! VERY BULLISH!!

Especially with the O/S maxed out…NO DILUTION!!

I hope everyone watched the video in my sticky. How many times do you see a steady uptrend in a sub penny stock, with NO news.

That's proves overall investor confidence is improving, making this a firm investment in the penny world. This is very rare to come across.

GO LONG!

P.s what I love about this stock is the huge number of longs holding tons of shares! Locking up that float for the big day!

BMSN: A Diamond in the Rough

Bio-Matrix Scientific Group (BMSN) may very well be one of those life-changing stocks. This company catches the eyes of many investors who trade based on technical analysis as well as those who believe the fundamentals behind the stock. This opportunity presents itself once in a lifetime: that is, finding a stock with as little downside and as much upside as possible, and when looking at what BMSN has to offer, the upside is unlimited. This is a very exciting time and things will start to happen very fast.

First off lets meet your Advisory Board
Weiping Min, M.D.

Dr. Min is Associate Professor, Department of Surgery at the University of Western Ontario. His clinical research is focused on using siRNA to inhibit disease modalities, including cancer and organ rejection. He earned graduate and medical degrees from Nanchang University Medical School and the Ph.D. degree from Kyushu University.

Vladimir Bogin M.D.
Dr. Bogin is the President and CEO of Cromos Pharma, a contract research organization that specializes in biopharmaceutical clinical outsourcing. He was formerly the Director of Boehringer Ingelheim in charge of the phase IV program for Dabigatran Etexilate. He studied at the Yale University School of Medicine and the University of Rochester School of Medicine and Dentistry.

David James Graham White, M.D., Ph.D.
Dr. White is a member of the Surgery and Immunology faculty of The Schulic School of Medicine, University of Western Ontario. He is one of the leading experts on using regenerative medicine transplant procedures to treat pancreatic conditions, including diabetes. He is also the Chief Scientific Officer of Sernova Corp and was formerly a Therapeutic Area Head for Novartis. He received the B.Sc. degree from the University of Surrey and the M.D. and Ph.D. degrees from Cambridge University.

Fundamentals:

Bio-Matrix Scientific Group’s (BMSN) and their wholly owned subsidiary have taken major strides in the past seven months. The company has gone from initiating pre-clinical trials at the end of 2012 for HemaXellerate to potentially having two IND’s in progress. Here is a complete list of all that has been accomplished.

Milestones Achieved:

1) Regen Biopharma Peer-Reviewed Publication Provides Preclinical Support for HemaXellerate™ Bone Marrow Failure Product
http://www.regenbiopharma.com/news/2013.01.24.html
2) Regen BioPharma Files Investigational New Drug (IND) Application with FDA on HemaXellerate™ Stem Cell Drug For Aplastic Anemia
http://www.regenbiopharma.com/news/2013.02.05.html
3) Bio-Matrix’ Regen Biopharma Executes LOI to Acquire Issued US Patent Covering Cancer Gene-Silencing Technology for its use in Treating Breast Cancer.
http://finance.yahoo.com/news/bio-matrix-regen-biopharma-executes-151230212.html
4) Regen BioPharma Recieves IND # From FDA for HemaXellerate
http://finance.yahoo.com/news/regen-biopharma-receives-ind-fda-135716810.html
5) Bio Matrix Scientific Group’s Regen Biopharma Acquires Cancer Vaccine Technology With Initial Focus on Breast Cancer
http://finance.yahoo.com/news/bio-matrix-scientific-groups-regen-123000619.html
6) Bio-Matrix Scientific Group’s Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program
http://finance.yahoo.com/news/bio-matrix-scientific-groups-regen-123000616.html

At times things may seem slow but in reality they are happening very fast!! Don’t miss this opportunity because you can’t wait a few months.

Upcoming Milestones:

All of these are happening within the next few months

1) Initiate HemaXellerate Trial: Q4 2013
2) File IND on Min technology: Q4 2013
3) Initiate Min technology Trail: Q4 2013



How Will BMSN Fund Clinical Trails?

***Remember that BMSN has $20,000,000 in funding just wairing for the trial of hemaXellerate from Southridge***

Bio-Matrix Scientific Group, Inc. Announces Newly Formed Stem Cell Subsidiary -- Regen BioPharma Inc., Secures $20,000,000 in Institutional Funding
Southridge Partners to Provide $20 Million in Funding for the Rapid Commercialization of Stem Cell Therapies
SAN DIEGO, CA--(Marketwire - Apr 30, 2012) - Bio-Matrix Scientific Group, Inc. (OTCQB: BMSN) (PINKSHEETS: BMSN) announced today it has formed a new subsidiary, Regen BioPharma, Inc. Regen BioPharma has developed a vertically-integrated structure for acquiring patents, performing accelerating preclinical and clinical development, and licensing or selling technology developed to large pharma companies in the area of stem cells.
To date, Regen BioPharma has reviewed more than 20,000 US issued patents covering stem cell related subject matter, created a shortlist of 30 promising technologies for rapid commercialization, and currently is in negotiations to license several of these. Once the technology is secured, the Company anticipates partnering with industry leading scientists, physicians, and service providers to complete the Investigational New Drug (IND)-enabling work and begin clinical trials.
"In biotechnology in general, and specifically in the area of regenerative medicine, the biggest value creation occurs for shareholders when a company files an IND and obtains human data that provides proof of safety and efficacy," said David R. Koos, Chairman and Chief Executive Officer of Bio-Matrix. "We are assembling the team and capabilities to in-license and evaluate technologies rapidly, then to develop the regulatory package and initiate clinical trials. Our business model and partnerships will allow us to take cell therapy products from discovery to FDA Phase II clinical trials in as short a period as 18 - 24 months."
The Company also announced that it has secured $20,000,000 in financing from Southridge Partners II, LP of Ridgefield, Connecticut.
This agreement grants the Company the option to sell and obligates Southridge to purchase up to $20,000,000 of common stock over its term. The per share price will be determined based on market prices in accordance with an agreed upon formula and the Company is not obligated to draw on the facility.
The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission to register the resale by Southridge of any shares issued to it under the agreement. Subject to the effectiveness of the registration statement and the satisfaction of other customary conditions, the Company may draw on the facility from time to time, as and when it determines appropriate, in accordance with the timing and volume provisions set forth in the agreement.


Valuation once both Clinical Trials have been initiated:

These prices do not include hype for mergers, acquisitions, deals, etc…

Outstanding Shares= 2Billion
Drug in Phase 1= 40 million USD
$80,000,000 market cap / 2,000,000,000 shares =
.04 by the end of september

This is roughly a 1,500% increase from the current prices within the next few months. Anticipation alone should drive the price upward.

Bio-Matrix Scientific group has just entered quarter 4 of their fiscal year and thus far have achieved every aspect of their timeline on time if not earlier than expected.
Now lets be conservative, and say that only one drug made it to Phase II by the end of the year. This would put the BMSN market cap at about $140,000,000, yielding a share price of .07.

So if both drugs were to make it on to phase II by the end of the year you would be seeing a share price of a dime (.1) solely based on expected market cap of two Phase II drugs divided by the outstanding share number. That does not account for anticipation price of mergers, buyouts, and funding. The sky is the limit for this stock!

What is MinTechnology?

Take a look at his website! KNOW WHAT YOU OWN!!! He is the real deal!
http://publish.uwo.ca/~mweiping/

What is HemaXellreate?
http://www.translational-medicine.com/content/pdf/1479-5876-10-231.pdf

Technicals:

Watch this quick video done by the brilliant guys at Bull Warrior Stocks and realize that the Stock is now in an uptrend. So for those of you looking for a firm investment with limited downside, BMSN is a great play! VERY BULLISH!!

Especially with the O/S maxed out…NO DILUTION!!

If we can break through 37's 40's will come today!

Here's something to think about,

I do not think the IND will get denied but I do believe there is another round of questioning, in which koos is not requires to pr about.

So if you think about it this way, the next pr will be a pr of approval. You shouldn't have to worry about a pr coming out saying that we are delayed because he does not have to disclose that information, just hold on tight, our time will come!

I asked a magic 8 ball 4 questions

1) will bmsn get news tomorrow?

Yes!

2) is it good news?

Probably

3) is it FDA approval?

Probably

4) am I wearing an orange shirt?

No way


I was not wearing an orange shirt. Coincidence? I think not

Min technology IND filing will be soon. This quarter it's expected. I feel like people have forgotten about this, and to me its better than hemax. So even if no news hits on the hemaxellerate trial, we should be expecting another IND to attract attention and build momentum.

So stop worrying people! Just hold on and stick it out.

That is a good point! Everyone may think that for every time they respond to questions a new 30 day period starts...which means this 30 days crap everyone's been talking about means nothing.

Any website for proof of that?

Guess it just means we all hold until the big day is here. I got no problems with that.

http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083533.pdf

middle of the second page in bold it states "I agree not to begin clinical investigations until 30 days after FDA’s receipt of the IND"

specifically saying after the FDA's RECEIPT, not when koos puts it in the mailbox. and we do not know when they actually received it

I think everyone is getting confused. On February 5th of this year, they filed the IND or hemaxellerate and then on march 18th they received the IND # and questions to be answered. That was a span of 41 days. It has been 32 days from the time they submitted the responses to those questions until now.

This means that the 30 days did not start then they filed it. It is when they receive it. It takes time to send things back and fourth. This goes for the FDA sending their answer back to koos as well.

Don't get all worried that if the 30 days are up it means were are denied but also don't get too certain that if these 30 days are up it means we are approved. The way I see it we still have a most another 10 days of waiting.

Been waiting for this day for 8 months, I'm staying long!